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Gliomas are characterised by local infiltration, migration of tumour cells across long distances and sustained angiogenesis; therefore,
proteins involved in these processes are most likely important. Such candidates are semaphorins involved in axon guidance and cell
migration. In addition, semaphorins regulate tumour progression and angiogenesis. For cell signalling, class-4 semaphorins bind directly to
plexins, whereas class-3 semaphorins require additional neuropilin (NRP) receptors that also bind VEGF165. The anti-angiogenic activity
of class-3 semaphorins can be explained by competition with VEGF165 for NRP binding. In this study, we analysed the expressions of
seven semaphorins of class-3, SEMA4D, VEGF and the NRP1 and NRP2 receptors in 38 adult glial tumours. In these tumours, SEMA3B,
SEMA3G and NRP2 expressions were related to prolonged survival. In addition, SEMA3D expression was reduced in high-grade as
compared with low-grade gliomas. In contrast, VEGF correlated with higher grade and poor survival. Thus, our data suggest a function
for a subset of class-3 semaphorins as inhibitors of tumour progression, and the prognostic value of the VEGF/SEMA3 balance in adult
gliomas. Moreover, in multivariate analysis, SEMA3G was found to be the only significant prognostic marker.
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Gliomas are the most frequent human primary brain tumours.
Malignant gliomas are characterised by local infiltration and
migration of tumour cells across long distances and, unlike other
types of cancer, the morbidity and mortality from most brain
tumours do not involve metastasis but rather local invasion of the
tumour preventing complete surgical resection. Today, the current
standard of care for patients with high-grade malignant gliomas
includes tumour resection followed by adjuvant radiotherapy (RT)
and chemotherapy (CT). However, the prolongation of survival
associated with CT is only equivalent to an absolute increase in
1-year survival of 6% (from 40 to 46%; Stewart, 2002). Recently, a
survival benefit was reported for glioblastoma patients treated with
temozolomide combined with RT (Stupp et al, 2007). This benefit
was significantly observed when the MGMT promoter encoding an
alkyltransferase is methylated (Hegi et al, 2005). Nevertheless,
despite advances in surgical and medical neuro-oncology, the
prognosis of patients with glioma remains poor.
Molecular biology studies have underscored the function of
oncogenes in glioblastoma progression, notably EGF, PDGF and
their receptors, and a variety of tumour suppressor genes,
particularly p16
INK4a, p14
ARF, PTEN, RB1 and TP53. Also, frequent
loss of heterozygosity at chromosomes 1p, 10p, 10q, 19q and 22q
suggests a participation of additional tumour suppressor genes
(Kleihues and Cavenee, 2000; Pietsch and Wiestler, 1997; Collins,
2002, 2007). However, the current knowledge of tumour genetics
does not always allow identifying clinically relevant factors
predictive of outcome or response to therapy. More detailed
knowledge of underlying mechanisms and their relevance for the
cancer process will allow targeting specific deregulated pathways,
leading to rational design of future treatment modalities according
to the biology of the individual tumours.
As local invasion and migration of tumour cells are pivotal
mechanisms in glioma progression, proteins involved in these
processes are most likely important. Such candidates are
semaphorins, a family of proteins expressed in the brain and
other tissues, that are involved in axon guidance and cell
migration. In vertebrates, semaphorins are represented by secreted
members (class-3 semaphorins), transmembranous members
(classes 4–6) and by one class-7 membrane-anchored protein
(Semaphorin Nomenclature Committee, 1999; Yazdani and
Terman, 2006). Membranous semaphorins, such as SEMA4D,
bind directly to plexins (Tamagnone et al, 1999), whereas
class-3 semaphorins require additional receptors, NRP1 or NRP2
neuropilins (He and Tessier-Lavigne, 1997; Kolodkin et al, 1997).
In the central nervous system, class-3 semaphorins mostly act
as chemorepulsive cues (Messersmith et al, 1995; Adams et al,
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s1997; Bagnard et al, 1998). In addition, semaphorins and NRPs
regulate a wide range of biological processes, including physiolo-
gical and tumour angiogenesis, tumour progression, immune
response and platelet function.
The involvement of class-3 semaphorins in angiogenesis can be
explained by NRP receptors shared between neuronal and
endothelial cells (ECs). In ECs, NRP1 enhances the interaction of
vascular endothelial growth factor, VEGF165, with its receptor
VEGFR2 and stimulates VEGF-mediated angiogenesis (Soker et al,
1998, 2002), whereas SEMA3s are inhibitory by competing with
VEGF165 for NRP binding (Miao et al, 1999). Thus, the ratio of
SEMA3 and VEGF expression levels might be an important
determinant for blood vessel and tumour development.
VEGF is a major permeability and pro-angiogenic factor that is
highly expressed in brain tumours (Plate et al, 1992) and is partly
responsible for the loss of the blood–brain barrier (Jain et al,
2007). Intra-tumoural levels of VEGF and its receptors were related
to the histological grade of gliomas (Schmidt et al, 1999) and with
tumour vascularity (Samoto et al, 1995). Elevated expression of the
VEGF165 receptor NRP1 was found in tumour cells from various
human cancers (Bielenberg and Klagsbrun, 2007).
In glioblastomas, NRP1 expression was detected in ECs of
proliferating vessels and in neoplastic astrocytes (Broholm and
Laursen, 2004). Moreover, NRP1 overexpression was related to
poor prognosis in human gliomas and with the malignancy of
astrocytic tumours (Osada et al, 2004; Hu et al, 2007). Increased
expression of NRP1 has also been detected in tumour cells from
clinical glioma samples, suggesting a link between NRP1 expres-
sion and glioma malignancy (Ding et al, 2000). Besides VEGF
binding, a novel mechanism was recently proposed for NRP1 to
promote tumour progression through the enhancement of
autocrine hepatocyte growth factor/scatter factor signalling
through c-Met (Hu et al, 2007; Matsushita et al, 2007). NRP2
could also participate in human glioma progression (Mariani et al,
2001).
To date, little is known about the implication of semaphorins in
gliomas. In 12 human glioma cell lines, Rieger et al (2003) showed
that SEMA3A and SEMA3C were always expressed, whereas only
some cell lines expressed NRP1, NRP2, plexins A1, A2 or B1.
Recently, on the basis of the Affimetrix gene chip analysis of
gliomas, it was shown that SEMA3B expression associated with poorer
overall survival (OS) when combined with the expressions of two
other genes, osteonectin/SPARC and doublecortex/doublecortin,
which have key functions in cellular migration processes (Rich
et al, 2005). However, SEMA3B, like SEMA3F, is described as a
tumour suppressor gene (Tomizawa et al, 2001; Tse et al, 2002).
SEMA3F acts as a tumour suppressor gene by reducing angiogen-
esis and metastasis, probably through the inhibition of integrin-
mediated adhesion and VEGF expression (Xiang et al, 2002;
Kessler et al, 2004; Bielenberg et al, 2004; Kusy et al, 2005;
Futamura et al, 2007; Potiron et al, 2007). SEMA3B and SEMA3F
are also direct p53 targets (Ochi et al, 2002; Futamura et al, 2007).
In contrast to these inhibitory semaphorins, SEMA3C, 3E, 5C, 6A,
6B may contribute to tumorigenesis or to tumour progression
(Neufeld et al, 2005). Also, the transmembranous semaphorin
SEMA4D has recently become a focus of intensive research owing
to its capacity to induce tumour cell invasiveness and angiogenesis
(Conrotto et al, 2004, 2005; Basile et al, 2006, 2007; Ch’ng et al,
2007). Thus, the role of semaphorins in human gliomas is
ambiguous. Moreover, to our knowledge, SEMA3D, SEMA3E,
SEMA3F and SEMA3G expressions in human gliomas were not
studied.
In this study, we analysed mRNA expression of class-3
semaphorins, in addition to SEMA4D, VEGF, NRP1 and NRP2
expressions, in 38 adult glial tumours. Statistical analysis indicated
that SEMA3B, SEMA3G and NRP2 expressions were related to
prolonged survival and that SEMA3D expression was reduced in
high-grade as compared with low-grade gliomas. In contrast,
VEGF expression was related to higher grade and poor survival.
Thus, our data suggest a function for a subset of class-3
semaphorins as inhibitors of tumour progression, and the
prognostic value of the VEGF/SEMA3 balance in adult gliomas.
In addition, in multivariate analysis, SEMA3G and age were found
to be the only significant prognostic markers.
PATIENTS AND METHODS
Patients
Tissues from 38 adult patients harbouring glial tumours including
11 low-grade and 27 high-grade gliomas were collected during
surgery at the Department of Neurological Surgery (University of
Poitiers, France), with signed informed consent of all patients and
the approval of the ethics committee of the Poitou-Charentes area.
These patients were free from any past medical history, especially
with regard to brain surgery, brain radiation therapy or CT. All
patients were treated between January 2002 and May 2003. Twenty-
two patients had a combined therapy that associated with surgery
plus RT and/or CT, whereas 16 patients had no RT. Tumour
diagnosis and grading were established according to the World
Health Organization (WHO) criteria (Kleihues et al, 2002) and
were systematically revised by two expert neuropathologists.
Distribution of patients in groups according to the WHO
pathology classification is described in Table 1.
Analysis of class-3 semaphorins, VEGF, NRP1 and NRP2
expressions
Tissue harvesting and preparation Per-operative pathology exam
permitted the checking of glial tumour diagnosis with samples
Table 1 Demographic and pathological characteristics of patients
Treatment Sex
n Pathology
Biopsy/surgery
+RT±CT
Biopsy/surgery
±CT
Age
(years) F M
Low grades 11 OAII: 7 3 8 42.5 3 8
ODII: 4 (35–67) (27%) (73%)
High grades 27 OAIII: 4
ODIII: 5 19 8 60.6 11 16
GBM: 18 (22–75) (41%) (59%)
CT¼chemotherapy; F¼female; GBM¼glioblastoma; II, III¼tumour grades according to the World Health Organization; M¼male; OA¼oligoastrocytoma;
OD¼oligodendroglioma; RT¼radiotherapy.
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sobtained from either open-sky surgery or stereotactic biopsies.
Each tumour sample was divided into two parts: one was dedicated
to smears and the second was immediately frozen in liquid
nitrogen in the operating room, and stored at  801C until usage.
Only samples containing at least 80% of tumour cells were
considered for quantitative real-time RT–PCR.
RNA isolation and cDNA preparation Total RNA was extracted
from 0.5 to 3mg of tumour tissues using the RNAeasy
s Mini Kit
(Qiagen, Courtaboeuf, France) and cDNA was prepared as
described earlier (Wager et al, 2006).
Quantitative real-time RT–PCR mRNA levels were measured by
quantitative real-time RT–PCR in the ABI PRISM 7000 sequence
detection system (Applied Biosystems, Courtaboeuf, France).
Primer sequences and the length of the PCR products are listed
in Supplementary Table 1. The specific amplification for all
transcripts was checked by DNA sequencing after DNA purifica-
tion from the unique band of the RT–PCR product obtained at the
right size by agarose gel electrophoresis and by the thermal
dissociation curves (Supplementary Figure S1). Amplification
efficiency was tested using serial dilutions of each specific PCR
product, and the quality of the amplification curves was similar to
the results we described in one of our previous study (Brambilla
et al, 2000). The quantitative real-time RT–PCR values for each
amplification for our cohort of patients are given in Supplemen-
tary Table 2. The reactions were carried out by using the SYBR
Green chemistry as described earlier (Brambilla et al, 2000; Wager
et al, 2006). The amount of target mRNA was normalised with the
endogenous GAPDH mRNA by the [2 DCt 1000] formula, where
DCt ¼ Cttarget   CtGAPDH. The values of the differences between the
Ct values for GAPDH mRNA and each tested transcript ranged
as follows: Ct SEMA3A Ct GAPDH: 5.8–16.7; Ct SEMA3B Ct
GAPDH: 5.3–10.1; Ct SEMA3C Ct GAPDH: 5.6–15.4; Ct SE-
MA3D Ct GAPDH: 7.5–21.6; Ct SEMA3E Ct GAPDH: 2.9–15.0;
Ct SEMA3F Ct GAPDH: 4.8–16.8, Ct SEMA3G Ct GAPDH: 7.7–
17.4; Ct SEMA4D Ct GAPDH: 6.8–10.8; Ct VEGF Ct GAPDH:
1.8–7.6; Ct NRP1 Ct GAPDH: 5.3–10.5; and Ct NRP2 Ct GAPDH:
4.0–10.3.
Statistical analysis
Data were collected from the date of diagnosis. Differences
between groups in the respective semaphorin distribution were
tested using the Mann–Whitney U-test. Correlation analyses were
performed by the method of Spearman. Overall survival was
analysed by calculating the time interval between the date of
diagnosis and the date of death from any cause, or the date of the
last follow-up for surviving patients, and then estimated by the
Kaplan and Meier method.
The following clinical and biological features were analysed as
potential prognostic factors: age, sex, grade (high vs low),
treatment (surgery and RT±CT vs others), semaphorins, NRPs
and VEGF. Tested transcripts were categorised in three groups
(low, medium and high expressor), such as age (low, medium,
high), according to their lower and higher respective quartile
values.
All variables were assessed in univariate analysis using the two-
tailed log-rank test. To summarise prognostic information,
variables found to be associated at the 10% level with the outcome
were entered into a Cox regression model on the basis of likelihood
ratio test. A stepdown procedure allowed those variables adding to
each other’s prognostic information to be retained. Levels of
significance were represented by P-values derived from two-sided
tests. A P-value o0.05 or less was considered to indicate statistical
significance. SAS v 8 (Statistical Analysis System, Cary, NC)
software package was used.
RESULTS
We studied by quantitative real-time RT–PCR the expression of
the seven semaphorins from class-3 (A-G), SEMA4D, NRP1, NRP2
and VEGF in 11 adult low-grade and 27 high-grade gliomas. The
largest distribution of the values was observed for SEMA3D,
whereas SEMA4D showed a narrower range distribution
(Figure 1A). There was no correlation between the expression
levels of each tested gene and the age of the patients. Interestingly,
SEMA3C and SEMA3F mRNA levels were statistically more
expressed in men than in women (P¼0.041 and P¼0.021,
respectively) (Figure 1B, Supplementary Table 2A).
Between low- and high-grade gliomas, there was a statistically
significant difference in SEMA3D and VEGF expressions. SEMA3D
was more expressed in low-grade than in high-grade gliomas
(P¼0.035). In contrast, VEGF was more expressed in high-grade
than in low-grade gliomas (P¼0.035) (Figure 1C and Supplemen-
tary Table 2B).
We also noticed several correlations between gene expressions
(Supplementary Table 3). Correlation between several semaphorin
expressions was found positive. The strongest correlation was
observed for SEMA4D, which correlated positively with SEMA3B
(Po10
 4), SEMA3D (Po10
 4) and SEMA3G (P¼0.001). SEMA3D
correlated positively with SEMA3B (P¼0.033) and SEMA3G
(Po10
 3). NRP1 and NRP2 were also positively correlated
(Po10
 3). In addition, SEMA3A and SEMA3B were inversely
correlated (P¼0.007). SEMA3B, SEMA3F and SEMA4D expres-
sions correlated positively with NRP1 (P¼0.012, P¼0.007 and
P¼0.009, respectively), whereas SEMA3D and SEMA3G expres-
sions correlated with NRP2 (P¼0.040 and P¼0.033, respectively).
In contrast, VEGF expression was not correlated with NRPs but
was inversely correlated with SEMA3D (Po10
 3), SEMA3G
(Po10
 4) and SEMA4D (P¼0.008) expressions.
To determine the clinical relevance of these findings, with regard
to patient outcome, we also assessed whether these biomarkers
were related to OS. Patients were divided in three groups as
follows: group 1 included patients whose expression for the tested
transcript was below the 25th quartile, group 2 for expression
between the 25th and 75th percentile values and group 3 for
expression above the 75th quartile. Results of the univariate
analysis are summarised in Table 2A. Among the tested
semaphorins, SEMA3B and SEMA3G mRNA levels proved to be
a prognostic marker for OS in our cohort including 11 low-grade
and 27 high-grade gliomas (P¼0.029 and P¼0.016, respectively)
(Figure 2A and B). All patients with lower SEMA3B mRNA
expression died within 20 months after diagnosis (group 1),
whereas a probability of death of 82 and 71% after 40 months was
observed in group 2 and 3 patients, respectively. The median OS
time for groups 1, 2 and 3 were 9 (95% CI: 3–14), 17 (95% CI:
11–25) and 24 (95% CI: 6–.), respectively. For SEMA3G, all patients
from group 1 who expressed lower levels of SEMA3G mRNA died
within 20 months, whereas the probability of death was 94 and 50%
after 40 months for group 2 and 3 patients, respectively. The
median OS times for groups 1, 2 and 3 were 7 (95% CI: 4–18), 14
(95% CI: 11–19), 24 (95% CI: 12–.), respectively.
VEGF expression was also a prognostic marker for OS
(P¼0.012) (Figure 2C). Among group 1 patients who presented
the lowest VEGF mRNA levels, 38% died after 36 months. The
median OS in this group was not reached (95% CI: 11–.). In
contrast, group 2 and 3 patients with higher mRNA expression
showed decreased rate of OS (86 and 89% of patients died within
20 months, respectively). The median OS times for groups 2 and 3
were 12 (95% CI: 6–14) and 19 (95% CI: 18–33), respectively.
Lastly, NRP2 mRNA levels could also be considered as a
prognostic marker of OS (P¼0.002) (Figure 2D). All patients with
lower NRP2 expression died within 20 months, whereas group 2
and 3 patients with higher NRP2 mRNA expression had prolonged
survival (71 and 63% of patients died after 40 months,
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srespectively). The median OS times for groups 1, 2 and 3 were 7
(95% CI: 4–14), 22 (95% CI: 12–.), 20 (95% CI: 8–.), respectively. It
can be noted that SEMA3A, SEMA3D and SEMA3E were also found
to be associated at a 10% level with the OS.
Among clinical features that were analysed, three of them were
statistically related with survival: age, grade (high vs low) and
treatment (surgery and RT±CT vs others). The 10 variables that
were identified in univariate analysis as possible prognostic factors
(Po0.10), namely age, grade, treatment, SEMA3A, SEMA3B,
SEMA3D, SEMA3E, SEMA3G, VEGF and NRP2 expressions, were
considered for multivariate analysis and entered into a Cox model.
Only two variables, age and SEMA3G, were selected by stepwise
regression with a P-value less than 0.05 (P¼0.009 and P¼0.011,
respectively) and remained considered as adding to each other’s
prognostic information. Patients with lower age and a higher
expression of SEMA3G had a better prognostic for OS (Table 2B).
It can be noted that sex was of no prognostic value by univariate
analysis, and when this factor was added into the Cox model for
adjustment on baseline characteristics, the results remained
strictly similar.
DISCUSSION
Semaphorins are involved in axon guidance, cell migration,
development, immunity, tumorigenesis and they regulate tumoural
S
E
M
A
3
A
S
E
M
A
3
B
S
E
M
A
3
C
S
E
M
A
3
D
S
E
M
A
3
E
S
E
M
A
3
F
S
E
M
A
3
G
N
R
P
1
N
R
P
2
V
E
G
F
S
E
M
A
4
D
512.000
0.001
256.000
0.003
0.007
0.015
0.030
0.060
0.130
0.250
0.500
1.000
2.000
4.000
11.000
16.000
32.000
64.000
128.000
A
P=0.041 P=0.021  
P=0.035 
P=0.035
Low
grade
High
grade
Low
grade
VEGF
512.000
0.001
256.000
0.003
0.007
0.015
0.030
0.050
0.130
0.250
0.500
1.000
2.000
4.000
11.000
16.000
32.000
64.000
128.000
512.000
0.001
256.000
0.003
0.007
0.015
0.030
0.050
0.130
0.250
0.500
1.000
2.000
4.000
11.000
16.000
32.000
64.000
128.000
Male Female Male Female
SEMA3C SEMA3F
SEMA3D
High
grade
B C
Figure 1 (A) Semaphorin, NRP and VEGF expressions in gliomas measured by quantitative real-time RT–PCR; (B) SEMA3C and SEMA3F expressions in
men and women; (C) SEMA3D and VEGF expressions in low- and high-grade gliomas. Results are expressed by ½2 DCt 1000], where
DCt ¼ Cttarget   CtGAPDH.
Semaphorin, neuropilin and VEGF in glial tumours
L Karayan-Tapon et al
1156
British Journal of Cancer (2008) 99(7), 1153–1160 & 2008 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sangiogenesis. To better clarify the potential function of sema-
phorins in the pathogenesis of adult gliomas characterised by
high migration potential, marked angiogenesis with endothelial
proliferation, severe hypoxia and tumour necrosis, we analysed by
quantitative real-time RT–PCR, the expressions of class-3
semaphorins (A–G) and their receptors NRP1 and NRP2 in 38
adult gliomas. The rational to select the expression of class-3
semaphorins and their NRP receptors is that several of these
semaphorins have been involved in tumorigenesis and because
NRPs are co-receptors for VEGF. The hypothesis is that SEMA3s
are competitive inhibitors of VEGF-NRP binding (Miao et al,
1999). It thus seemed reasonable to limit the analysis to SEMA3
and NRP expressions on one hand and to VEGF on the other hand.
Other specific SEMA3 functions involve plexins as co-receptors
that elicit intracellular signals.
In our study, gene expression was compared between tumours
as no normal brain sample was available. Resections from epileptic
patients are often considered as normal control. However, altered
semaphorin expression and NRPs involvement have been reported
in epilepsy (for review see Yaron and Zheng, 2007). In mice,
Sema3F is downregulated in an epileptogenic-sensitive mice model
but not in a resistant one (Yang et al, 2005). These results are
supported by previous experiments in rats that develop epilepsy
after kainic acid injection with the reduction of Sema3F and
Sema3C expressions in the hippocampus (Barnes et al, 2003). In
another model, during the process of electrically induced
epileptogenesis in rats, a transient reduction in Sema3A expression
was described and correlated to mossy fibre sprouting believed to
have a critical function in the hyperexcitability of the hippocampus
in temporal lobe epilepsy of patients (Holtmaat et al, 2003). Direct
functional evidence for a function of semaphorins and their
receptors in epilepsy is supported by Sema3F knockout mice
(Sahay et al, 2005) and some NRP2 mutant mice (Giger et al, 2000;
Chen et al, 2000) that are more prone to seizures. Therefore, we
cannot consider resection pieces of epileptic patients as control for
normal tissue.
With these limitations, we observed that class-3 semaphorins
(A–G) and their receptors NRP1/NRP2 as well as SEMA4D and
VEGF expressions were heterogeneous between samples, which
suggest a differential expression of these genes between tumours.
Consistent with several data (Jain et al, 2007), we found that VEGF
Table 2B Relationship between factors and overall survival in multi-
variate analysis (final Cox model)
Variable
Hazard
ratio
95% Hazard ratio
confidence limits P-value
Age 1.062 1.015–1.111 0.009
SEMA3G 0.400 0.198–0.810 0.011
Gene expression was measured by quantitative real-time RT–PCR.
Table 2A Relationship between factors and overall survival in univariate
analysis
Variable Category
Log-rank test
(P-value)
Age (years) o43/43–65/465 0.001
Sex Male/female 0.866
Grade High/low 0.002
Treatment Surgery and RT±CT vs others 0.024
SEMA3A expression Low/medium/high 0.091
SEMA3B expression Low/medium/high 0.029
SEMA3C expression Low/medium/high 0.613
SEMA3D expression Low/medium/high 0.087
SEMA3E expression Low/medium/high 0.091
SEMA3F expression Low/medium/high 0.360
SEMA3G expression Low/medium/high 0.016
SEMA4D expression Low/medium/high 0.131
NPR1 expression Low/medium/high 0.161
NPR2 expression Low/medium/high 0.002
VEGF expression Low/medium/high 0.012
CT¼chemotherapy; RT¼radiotherapy. Gene expression was measured by
quantitative real-time RT–PCR.
0
Months since diagnosis
6 1 21 82 43 0
SEMA3B
High expression
(n=7)
Medium expression (n=17)
Low expression 
(n=8)
P=0.029
0.0
1.0
0.1
0.2
0.4
0.3
0.9
0.8
0.7
0.6
0.5
P
r
o
b
a
b
i
l
i
t
y
 
o
f
 
s
u
r
v
i
v
a
l
36 48 42 0
Months since diagnosis
6 1 21 82 43 03 64 24 8
0.0
1.0
0.1
0.2
0.4
0.3
0.9
0.8
0.7
0.6
0.5
P
r
o
b
a
b
i
l
i
t
y
 
o
f
 
s
u
r
v
i
v
a
l
SEMA3G
Low expression 
(n=8)
P=0.016
High expression (n=8)
Medium expression (n=16)
0
Months since diagnosis
6 1 21 82 43 03 64 24 8 0
Months since diagnosis
6 1 21 82 43 03 64 24 8
0.0
1.0
0.1
0.2
0.4
0.3
0.9
0.8
0.7
0.6
0.5
P
r
o
b
a
b
i
l
i
t
y
 
o
f
 
s
u
r
v
i
v
a
l 1.0
0.1
0.2
0.4
0.3
0.9
0.8
0.7
0.6
0.5
P
r
o
b
a
b
i
l
i
t
y
 
o
f
 
s
u
r
v
i
v
a
l
0.0
VEGF NRP2
Low expression (n=8)
High expression
(n=9)
Medium expression (n=21)
P=0.012 P=0.002
Low expression 
(n=9)
Medium expression (n=18)
High expression (n=8)
AB
CD
Figure 2 Kaplan–Meier survival curves for 38 patients with glial tumours, for SEMA3B (A), SEMA3G (B), VEGF (C) and NRP2 (D) expressions. Three
groups of patients were defined as follows: group 1 included patients whose expression for the tested transcript was below the 25th quartile, group 2 for
expression included between the 25th and 75th percentile values and group 3 for expression above the 75th quartile.
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swas significantly more expressed in high-grade gliomas as
compared with low-grade gliomas. In contrast, we observed that
SEMA3D was statistically more expressed in low-grade than in
high-grade gliomas, suggesting that its loss is involved in tumour
progression to high grades. To our knowledge, no study was
performed for SEMA3D expression in tumours. For the other
studied genes (SEMA3A, B, C, E, F, G, NRP1, NRP2 and SEMA4D),
we did not observe statistical difference between low- and high-
grade gliomas. As normal tissue was not available, we can only
speculate that either gene expression is not changed in gliomas as
compared with normal tissue or that change in expression is an
early event in tumour progression.
An interesting observation was that SEMA3C and SEMA3F were
statistically more expressed in glial tumours from men than from
women, suggesting a possible hormonal regulation of these genes.
In addition, we observed several correlations between sema-
phorin expressions but we are unable to explain them. Of
particular interest were (i) the positive correlation between
SEMA4D and SEMA3B, D, G, and (ii) the negative correlation
between VEGF and SEMA3D, G and 4D. For this last point, several
studies reported VEGF expression inhibition by semaphorins. For
example, when VEGF165-stimulated multiple myeloma ECs were
exposed to SEMA3A, a time-dependent decrease of endogenous
VEGF165 mRNA was observed (Vacca et al, 2006). Similarly, VEGF
in addition to NRP1 was downregulated in SEMA3B-transfected
ovarian adenocarcinoma cells (Naylor, AACR Meeting 2003, Poster
no. 4935). In addition, we showed that SEMA3F protein correlated
negatively with VEGF in lung cancer (Brambilla et al, 2000), and
recently demonstrated that SEMA3F reduced VEGF mRNA level
and HIF-1a protein level (Potiron et al, 2007). Lastly, intra-
peritoneal administration of recombinant extracellular SEMA6A in
mouse inhibited both bFGF/VEGF and tumour cell line-induced
neovascularisation (Dhanabal et al, 2005). One can speculate that
SEMA3D and SEMA3G could have similar properties and behave
like anti-angiogenic proteins in gliomas. It can be noted that
SEMA3F, now recognised as a tumour suppressor gene (Xiang
et al, 2002; Kessler et al, 2004; Bielenberg et al, 2004; Kusy et al,
2005; Futamura et al, 2007) with antiangiogenic (Kessler et al,
2004; Futamura et al, 2007) and anti-metastatic properties
(Bielenberg et al, 2004), did not show up as an important gene
in our cohort of patients with gliomas. One explanation could be
that SEMA3F protein is mostly present in nerve fibres and never
detectable in glial cells and blood vessel in the adult human brain
(Hirsch et al, 1999).
The negative correlation between VEGF and SEMA4D is
puzzling as SEMA4D triggers invasive growth of epithelial cells
(Giordano et al, 2002) and is described as proangiogenic through
Met recruitment by plexin B1 (Conrotto et al, 2005) and
stimulation of Rho-initiated pathways (Basile et al, 2004, 2006).
However, SEMA4D is rare in B-cell non-Hodgkin’s lymphomas,
suggesting that its loss might lead to decreased cell adhesion,
increased mobility and metastatic potential (Dorfman et al, 1998).
SEMA4D also exerts important functions in the immune system
and could be a guidance signal that directs the recruitment of
the immune cells (for review Elhabazi et al, 2003). Therefore,
the involvement of SEMA4D in immunity during tumour
development is not known and SEMA4D function in cancer
remains ambiguous.
Of particular interest with regard to patient outcome, we found
that higher SEMA3B and SEMA3G expressions were related to
better outcome. Our observation is in accordance with the tumour
suppressor activity of SEMA3B (Tomizawa et al, 2001; Tse et al,
2002). On the contrary, it was shown that low SEMA3B expression
associated with poorer OS in gliomas, but when associated with
expression of two other genes, osteonectin/SPARC and double-
cortex/doublecortin (Rich et al, 2005). However, the very recent
data by Rolny et al (2008) suggest a reconsideration of this
semaphorin as a multifaceted regulator of cancer progression:
SEMA3B inhibited tumour growth in mice but simultaneously and
unexpectedly triggered metastasis by activating the signalling
kinase p38. Regarding SEMA3G, a recently identified semaphorin
(Taniguchi et al, 2005), no data have been published to our
knowledge about its function in tumours. When a multivariate Cox
analysis was performed, SEMA3G was found to be, with the age,
the only significant prognostic marker. Our study had some
limitations as mRNA expression is not always correlated with
protein expression; moreover, an aberrant localisation of the
protein impaired its activity. Because there is no commercially
available/relevant antibody to confirm the expression pattern of
SEMA3G, we cannot correlate SEMA3G mRNA and protein levels.
We also observed that higher NRP2 expression or lower VEGF
expressions were related to better outcome. Interestingly, NRP2 is
the receptor of SEMA3G (Taniguchi et al, 2005). As VEGF165 binds
to NRP2 (Gluzman-Poltorak et al, 2000), competition between
SEMA3B/3G and VEGF165 for binding to NRP2 might exist in
gliomas as demonstrated for SEMA3A and NRP1 in ECs (Miao
et al, 1999).
We did not find any relation between NRP1 expression and OS
in our series. This result was surprising because NRP1 is expressed
in many tumours, and in some models, NRP1 has been shown to
increase tumorigenicity (Miao et al, 2000). NRP1 was also
significantly correlated with poor prognosis in non-small-cell lung
carcinomas (Kawakami et al, 2002), and blocking VEGF and NRP1
significantly increased survival (Pan et al, 2007).
In conclusion, SEMA3B, SEMA3G and NRP2 expressions
were related to prolonged survival of adult patients with glial
tumours. SEMA3D expression was reduced in high-grade as
compared with low-grade gliomas and the opposite was seen for
VEGF expression. Thus, we propose the involvement of a subset of
class-3 semaphorins as inhibitors of glioma progression and
suggest that the balance VEGF/SEMA3 might be of prognostic
value. SEMA3G was found to be the only significant prognostic
marker in gliomas when a multivariate analysis was performed.
As very little data have been published with regard to this
semaphorin, more studies are necessary to assess its function in
tumorigenesis.
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